Intensive monitoring of newly marketed drugs or those for which there is limited information on long-term use, in order to be able to identify possible adverse effects not covered by the initial registration, as these can only be observed in real life when a large number of people have used a medicinal product over a long period of time.
Intensive drug monitoring | Black Triangle
This information is necessary for European health authorities to ensure that the benefit remains greater than the risk.
